Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By

Showing results 21 - 30 of 44

Selected Filters:
8 August 2022

Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women

This press release provides an overview of the new findings from HPTN 084, a trial of the HIV Prevention Trials Network studying injectable cabotegravir for PrEP among cisgender women. The updated results show reductions in HIV incidence were sustained in the 12 months following unblinding and were presented at the AIDS 2022 conference in Montreal.

Research

External Link
5 August 2022

WHO Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention

WHO guidelines, issued in 2022, recommend injectable cabotegravir (CAB) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. These guidelines provide considerations to support managers, policy makers, researchers, health workers, communities, and other stakeholders in the implementation of projects and programs for injectable CAB for PrEP. It…

Normative Guidance/Policies

Document
4 August 2022

AVAC, BMGF, CIFF, MedAccess, Unitaid and ViiV Healthcare announce collaboration to catalyse more affordable access to long- acting injectable cabotegravir for HIV prevention

AVAC press release announcing a new collaboration focused on pricing, innovative funding mechanisms, tracking regulatory approvals, and ensuring the inclusion of civil society in key planning and decision making to speed access to injectable cabotegravir (CAB) for PrEP. Launched at the 24th International AIDS Conference, this collaboration includes AVAC, the Bill and Melinda Gates Foundation,…

Community/Advocacy

External Link
4 August 2022

ViiV and Medicines Patent Pool Sign Voluntary Licensing Agreement for Cabotegravir for PrEP

ViiV Healthcare and the Medicines Patent Pool (MPP) announced the signing of a new voluntary licensing agreement for patents relating to cabotegravir for PrEP to help enable access in least developed, low-income, lower middle-income and Sub-Saharan African countries.

Service Delivery, Supply Chain Management

External Link
4 August 2022

Coordinating Implementation Science for CAB for PrEP

As implementation studies for injectable cabotegravir (CAB) for PrEP are being considered and as programs shift towards choice-based models for HIV prevention, there is a chance to correct for missed opportunities with oral PrEP rollout, understand client preferences and patterns of use, and ensure more effective coordination across geographies, populations, and projects. To facilitate this…

Research

Document
4 August 2022

BioPIC CAB for PrEP Study Compendium

This compendium provides detail on planned and ongoing studies related to landscaping, product introduction, introduction studies, and implementation research for Cabotegravir for PrEP and is a companion to the Implementation Study Tracker. If you would like to add your study to the compendium, please contact Catherine Verde Hashim.

Research

Presentation
3 August 2022

Implementation Study Tracker

This study tracker, produced under the BioPIC platform, reflects all currently known activities relating to landscaping, product introduction, introduction studies, and implementation research for new biomedical PrEP options, including cabotegravir for PrEP and the dapivirine vaginal ring. To update or add any activities missing from the tracker, please contact Catherine Verde Hashim to ensure they…

Research

Document
7 July 2022

An Advocates’ Primer on Long-Acting Injectable Cabotegravir for PrEP

Results from two large-scale efficacy trials found that injectable cabotegravir (CAB-LA), given every two months, was effective as a form of pre-exposure prophylaxis (PrEP) in preventing HIV in gay men and other men who have sex with men, transgender women who have sex with men, and cisgender women. CAB-LA was developed by ViiV Healthcare and…

Community/Advocacy

External Link
7 July 2022

Results from the HPTN 083 Trial

The HIV Prevention Trials Network (HPTN) held a community webinar to discuss the preliminary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP) in transgender women and cisgender men who have sex…

Research

External Link
7 July 2022

HPTN 084

The HIV Prevention Trials Network (HPTN) hosted a community webinar to discuss the primary results of HPTN 084, a randomized, double-blind controlled trial designed to evaluate the efficacy and safety of long-acting injectable cabotegravir (CAB LA) to prevent the sexual acquisition of HIV in cisgender women in sub-Saharan Africa.

Research

External Link